Application of hydroquinone derivative in inhibiting activity of klebsiella pneumoniae and preparing anti-klebsiella pneumoniae medicine
Through the synthesis and application of hydroquinone derivative A, the problem of drug resistance of Klebsiella pneumoniae was solved, significantly inhibited the activity of Klebsiella pneumoniae, and verified its preparation of anti-Klebsiella pneumoniae drugs. The effectiveness of the disease has achieved effective antibacterial effect on multidrug-resistant strains.
Patent Information
- Application Number
- CN202410991658.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-23
AI Technical Summary
Klebsiella pneumoniae has severe multidrug resistance to commonly used antibacterial drugs, resulting in increased hospital infection rates and failed treatment. The existing studies lack effective hydroquinone derivatives for the inhibition of Klebsiella pneumoniae.
采用氢醌类衍生物A作为支架合成的化合物,通过卤化和五元杂环取代衍生物,显著抑制肺炎克雷伯菌活性,并用于制备抗肺炎克雷伯菌药物,利用斑马鱼感染模型验证 Its safety and efficacy.
At safe concentrations, hydroquinone derivative A significantly inhibits the activity of Klebsiella pneumoniae and can be effectively used in the preparation of anti-Klebsiella pneumoniae drugs, significantly reducing the growth of Klebsiella pneumoniae, proving that it is in multidrug-resistant strains antibacterial effect in.
Smart Images

Figure CN118903076A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and particularly relates to the application of hydroquinone derivatives in inhibiting the activity of Klebsiella pneumoniae and preparing anti-Klebsiella pneumoniae drugs. Background Art
[0002] Klebsiella pneumoniae is a Gram-negative bacterium that can colonize and multiply in the host's pharynx and gastrointestinal tract to form colonies. In cases of reduced immunity, endotracheal intubation, or abuse of antibiotics, the pathogenic bacteria can enter the lungs through inhalation, swallowing, intubation, etc., causing infection and pneumonia. Klebsiella pneumoniae pneumonia can cause severe pneumonia, bronchitis, infantile meningitis, enteritis, traumatic infection, urinary tract infection, sepsis, etc.
[0003] Klebsiella pneumoniae (Kpn) is one of the important pathogens of clinical isolation and hospital infection. With the widespread use of broad-spectrum antibiotics such as β-lactams and aminoglycosides, bacteria are prone to produce extended-spectrum β-lactamases (ESBLs) and cephalosporinases (AmpC enzymes) and aminoglycoside modifying enzymes (AMEs), showing serious multidrug resistance to commonly used drugs including third-generation cephalosporins and aminoglycosides. The hospital infection rate caused by Klebsiella pneumoniae has increased year by year in recent years, and the continuous increase of multidrug-resistant strains often leads to the failure of clinical antimicrobial drug treatment and prolonged course of disease. The resistance mechanism of Klebsiella pneumoniae mainly includes the production of β-lactamases, the formation of biofilms, the loss of outer membrane porins, and the active efflux of antimicrobial drugs. The horizontal spread of antimicrobial resistance genes is an important reason for the clinical aggravation of multidrug-resistant strains.
[0004] Quinone / hydroquinone derivatives are an important class of marine natural products. Most natural quinone / hydroquinones are isolated from marine sponges, brown algae and fungi. They have a wide range of biological activities, including anti-tumor, anti-viral and anti-bacterial activities, especially anti-microbial activities against methicillin-resistant and multi-drug-resistant strains. In most cases, quinone / hydroquinone derivatives act as important electron transfer mediators in organisms through reversible redox processes. In the inventors' early research, three bioactive hydroquinone derivatives extracted from the mangrove fungus of the South China Sea were synthesized using o-methylhydroquinone as a scaffold, and their structures were characterized by nuclear magnetic resonance spectroscopy and high-resolution mass spectrometry. The synthesis method and characterization results are detailed in the literature "Li H, Jiang J, Liu Z, Lin S, Xia G, Xia X, Ding B, He L, Lu Y, She Z. Peniphenones A-Dfrom the mangrove fungus Penicillium dipodomyicola HN4-3A as inhibitors of Mycobacterium tuberculosis phosphatase MptpB. J Nat Prod.
[0005] 2014;77(4):800-806”.
[0006] Although quinone / hydroquinone derivatives have been found to have good antibacterial activity, there has been no research on the inhibition of hydroquinone derivatives on Klebsiella pneumoniae in existing studies. Therefore, as the infection rate and drug resistance of Klebsiella pneumoniae are gradually increasing, studying the role of quinone / hydroquinone derivatives in the inhibition of Klebsiella pneumoniae has a positive impact. Summary of the invention
[0007] In view of the deficiencies in the prior art, the present invention provides an application of hydroquinone derivatives in inhibiting Klebsiella pneumoniae.
[0008] The present invention provides the use of hydroquinone derivatives in inhibiting the activity of Klebsiella pneumoniae, wherein the hydroquinone derivatives are: For the convenience of description, the above hydroquinone derivatives are referred to as hydroquinone derivatives A for short.
[0009] Application of hydroquinone derivatives in inhibiting the activity of Klebsiella pneumoniae, wherein the hydroquinone derivatives also include The derivative of the hydroquinone derivative A may be a compound in which one or more hydroxyl groups of the hydroquinone derivative A are halogenated, such as the hydroxyl group is halogenated to -F, -Cl, -Br or -I; the derivative of the hydroquinone derivative A may also be a compound in which the hydroquinone derivative A is substituted with a five-membered heterocyclic ring, such as pyrrole, furan, thiophene, oxazole, thiazole, pyrazole, imidazole, triazole and tetrazole.
[0010] The present invention also provides the use of hydroquinone derivatives in the preparation of anti-Klebsiella pneumoniae drugs, wherein the hydroquinone derivatives are:
[0011] Application of hydroquinone derivatives in the preparation of anti-Klebsiella pneumoniae drugs, the hydroquinone derivatives also include The derivative of the hydroquinone derivative A may be a compound in which one or more hydroxyl groups of the hydroquinone derivative A are halogenated, such as the hydroxyl group is halogenated to -F, -Cl, -Br or -I; the derivative of the hydroquinone derivative A may also be a compound in which the hydroquinone derivative A is substituted with a five-membered heterocyclic ring, such as pyrrole, furan, thiophene, oxazole, thiazole, pyrazole, imidazole, triazole and tetrazole.
[0012] The hydroquinone derivative A can be synthesized by using o-methylhydroquinone as a scaffold, and the simplified reaction formula is:
[0013]
[0014] Beneficial effects of this program:
[0015] The present invention discloses that, under a safe concentration, a hydroquinone derivative A can significantly inhibit the activity of Klebsiella pneumoniae. Specifically, the present invention uses zebrafish as a model animal to construct a Klebsiella pneumoniae-like infection model, and uses fluorescence intensity analysis of FITC fluorescent dye to prove that the hydroquinone derivative A can significantly inhibit the activity of Klebsiella pneumoniae, and can be used to prepare drugs against Klebsiella pneumoniae. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The above and other purposes, features and advantages of the present invention will become more clear by more specific description of the preferred embodiments of the present invention shown in the accompanying drawings. The same reference numerals indicate the same parts in all the accompanying drawings, and the accompanying drawings are not deliberately scaled to the actual size, and the focus is on illustrating the main purpose of the present invention.
[0017] Figure 1 The maximum safe concentration test result of the hydroquinone derivative A provided by the present invention for zebrafish larvae;
[0018] Figure 2 The present invention provides a zebrafish model fluorescence test result diagram of the hydroquinone derivative A inhibiting the activity of Klebsiella pneumoniae;
[0019] Figure 3 The present invention provides a schematic diagram of fluorescence intensity of a zebrafish model fluorescence test showing that hydroquinone derivative A inhibits the activity of Klebsiella pneumoniae. DETAILED DESCRIPTION
[0020] The technical solution of the present invention is further described in detail below in conjunction with specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0021] Hydroquinone derivative A is a biologically active hydroquinone derivative extracted from mangrove fungi in the South China Sea. It can now be artificially synthesized, but the specific application of hydroquinone derivative A is still in the research stage. There are currently no reports publicly using hydroquinone derivative A to inhibit the activity of Klebsiella pneumoniae or to prepare drugs against Klebsiella pneumoniae.
[0022] The following examples are experiments to verify the safety and efficacy of hydroquinone derivative A. The experimental results were tested by statistical methods. All experiments were repeated at least 3 times independently. The results were expressed as mean values and standard errors. All statistical analyses used P < 0.01 as the test standard for significant statistical differences.
[0023] Due to the characteristics of convenient zebrafish breeding, short reproductive cycle, large egg production, in vitro fertilization, in vitro development, transparent embryos, etc., zebrafish has become a new favorite in life science research and is widely used in studying the infection process of mammals caused by various pathogens and viruses and the development of antibacterial drugs. The present invention uses zebrafish as a model animal to construct a Klebsiella pneumoniae infection model.
[0024] Example 1 Test on the maximum safe concentration of hydroquinone derivative A for zebrafish larvae
[0025] Before exploring the activity of hydroquinone derivative A against Klebsiella pneumoniae infection, a safety evaluation is required, that is, the maximum safe concentration of hydroquinone derivative A for zebrafish larvae must be determined first. Biosafety is a prerequisite for candidate drugs to exert their efficacy characteristics. First, the safety of hydroquinone derivative A in zebrafish larvae was studied: zebrafish larvae were incubated with hydroquinone derivative A at different concentration gradients (0.25, 0.5, 1, 2, 4 μM) for 96 hours, and the number of normal, deformed and dead zebrafish embryos in each group after 72 hours and 96 hours of incubation was counted. The results are shown in Tables 1 and Figure 1 shown.
[0026] Table 1 Maximum safe concentration test of hydroquinone derivative A for zebrafish larvae
[0027]
[0028] From Table 1 and Figure 1 It can be seen that the co-culture of hydroquinone derivative A with concentrations of 0.25 μM, 0.5 μM and 1 μM with zebrafish larvae does not cause deformity and death in zebrafish embryos, while 2 μM and 4 μM hydroquinone derivative A can cause deformity and death in zebrafish embryos. In summary, the maximum safe concentration of hydroquinone derivative A for zebrafish is 1 μM when co-cultured for 96 hours. Therefore, the following experiment of the present invention explores the application of hydroquinone derivative A's anti-Klebsiella pneumoniae activity at a safe concentration of 1 μM of hydroquinone derivative A.
[0029] Example 2 Experimental study on the inhibitory effect of hydroquinone derivative A on Klebsiella pneumoniae
[0030] 1. Construction of a zebrafish model of Klebsiella pneumoniae infection
[0031] Klebsiella pneumoniae was stained with FITC (fluorescein isothiocyanate) fluorescent dye under light-proof conditions. After incubation in a dark room for 1 h, the staining working solution was centrifuged and cleaned. After being rinsed three times with PBS (polybutylene succinate), a bacterial suspension (1×10 9 CFU / mL) for later use. 24hpf (hours-post fertilization) zebrafish embryos were decapped using 0.25% trypsin and incubated in a 28°C biochemical incubator until 48hpf; then zebrafish larvae were anesthetized using 0.02% tricaine and placed on an agar plate, and 2nL of the above-stained bacteria were injected into the yolk sac of zebrafish larvae using a microinjector (PV850, Shenzhen Decheng Instrument Technology Co., Ltd.). After the injection, the larvae were rinsed at least twice with embryo culture medium without methylene blue to remove tricaine and free bacteria.
[0032] The zebrafish models infected with Klebsiella pneumoniae were placed on a glass slide, and the bacterial distribution was observed one by one under a fluorescence microscope (NIB950-FL, Ningbo Yongxin Optics Co., Ltd.). The zebrafish models with uniform distribution and similar number of Klebsiella pneumoniae were selected and randomly divided into four groups, namely blank control group, experimental group 1, experimental group 2 and experimental group 3. The zebrafish models of the above groups were placed in a 48-well plate, and 12 duplicate wells were set for each group, with one fish in each well.
[0033] 2. Test methods
[0034] (1) Set up groups
[0035] A zebrafish model with uniform distribution and similar number of Klebsiella pneumoniae was selected and randomly divided into four groups, namely blank control group, experimental group 1, experimental group 2 and experimental group 3.
[0036] Prepare hydroquinone derivative A solutions of different concentrations: dissolve hydroquinone derivative A in 0.1% DMSO (dimethyl sulfoxide) to form hydroquinone derivative A solutions with concentrations of 0.25 μM, 0.5 μM and 1 μM, corresponding to experimental group 1, experimental group 2 and experimental group 3, respectively.
[0037] In the blank control group, an equal amount of 0.1% DMSO was added to each replicate well, in experimental group 1, an equal amount of 0.25 μM hydroquinone derivative A was added to each replicate well, in experimental group 2, an equal amount of 0.5 μM hydroquinone derivative A was added to each replicate well, and in experimental group 3, an equal amount of 1 μM hydroquinone derivative A was added to each replicate well, and the additives were cultured with the zebrafish model for 48 h.
[0038] (2) Results Statistics
[0039] After 48 hours of intervention with DMSO and hydroquinone derivative A, the zebrafish infected with Klebsiella pneumoniae were placed under a fluorescence microscope to record the distribution of Klebsiella pneumoniae in the zebrafish and to calculate the fluorescence intensity. The results are shown in Table 2. Figure 2 and Figure 3 shown.
[0040] Table 2 Statistics of fluorescence intensity of Klebsiella pneumoniae in zebrafish
[0041]
[0042] Figure 2 (a)-(d) are comparison graphs of the green fluorescence intensity of the yolk sac of the four groups of Klebsiella pneumoniae-infected zebrafish models at 0h and 48h of the experiment.
[0043] Figure (a) is a comparison of the green fluorescence intensity of the yolk sac of the zebrafish model infected with Klebsiella pneumoniae in the blank control group at 0h and 48h of the experiment. It can be seen that the green fluorescence intensity of the zebrafish yolk sac was significantly stronger than that at 0h of the experiment 48h after the experiment, indicating that in the case of blank control, that is, without drug intervention, Klebsiella pneumoniae further infected the zebrafish after 48h. Figure 3 It can also be seen that at 0 h of the experiment, the green fluorescence intensity of the zebrafish model was 809 au, while after 48 h of the experiment, the green fluorescence intensity of the zebrafish model was 1090 au, and the green fluorescence intensity increased significantly.
[0044] Figure (b) is a comparison of the green fluorescence intensity of the yolk sac of the zebrafish model infected with Klebsiella pneumoniae in experimental group 1 at 0h and 48h of the experiment. It can be seen that after 48h of the experiment, the green fluorescence intensity of the zebrafish yolk sac was close to that at 0h of the experiment, indicating that in the case of experimental group 1 (hydroquinone derivative A concentration of 0.25μM), that is, under the intervention of 0.25μM hydroquinone derivative A, Klebsiella pneumoniae did not further infect zebrafish after 48h, and there was a certain inhibitory effect on Klebsiella pneumoniae compared with the blank experimental group. Figure 3 It can also be seen that at 0 h of the experiment, the green fluorescence intensity of the zebrafish model was 891 au, and after 48 h of the experiment, the green fluorescence intensity of the zebrafish model was 922 au, and the green fluorescence intensity remained basically the same.
[0045] Figure (c) is a comparison chart of the green fluorescence intensity of the yolk sac of the zebrafish model infected with Klebsiella pneumoniae in experimental group 2 at 0h and 48h of the experiment. It can be seen that after 48h of the experiment, the green fluorescence intensity of the zebrafish yolk sac was lower than that at 0h of the experiment, indicating that in the case of experimental group 1 (hydroquinone derivative A concentration of 0.5μM), that is, under the intervention of 0.5μM hydroquinone derivative A, Klebsiella pneumoniae was effectively inhibited after 48h compared with the test at 0h; and compared with the blank experimental group, there was a significant inhibitory effect on Klebsiella pneumoniae. Figure 3 It can also be seen that at 0 h of the experiment, the green fluorescence intensity of the zebrafish model was 823 au, while after 48 h of the experiment, the green fluorescence intensity of the zebrafish model was 781 au, and the green fluorescence intensity decreased (P<0.01).
[0046] Figure (d) is a comparison chart of the green fluorescence intensity of the yolk sac of the zebrafish model infected with Klebsiella pneumoniae in experimental group 3 at 0h and 48h of the experiment. It can be seen that after 48h of the experiment, the green fluorescence intensity of the zebrafish yolk sac was significantly lower than that at 0h of the experiment, indicating that in the case of experimental group 1 (hydroquinone derivative A concentration of 1μM), that is, under the intervention of 1μM hydroquinone derivative A, Klebsiella pneumoniae was significantly inhibited after 48h compared with the 0h of the experiment; and compared with the blank experimental group, there was a significant inhibitory effect on Klebsiella pneumoniae. Figure 3 It can also be seen that at 0 h of the experiment, the green fluorescence intensity of the zebrafish model was 816 au, while after 48 h of the experiment, the green fluorescence intensity of the zebrafish model was 419 au, and the green fluorescence intensity was significantly reduced (P<0.001).
[0047] In summary, the statistical analysis of fluorescence intensity showed that when the treatment concentration of hydroquinone derivative A was ≥0.5 μM, it significantly inhibited the growth of Klebsiella pneumoniae in zebrafish (P<0.01), and can be used to prepare anti-Klebsiella pneumoniae drugs.
[0048] The above are only preferred embodiments of the present invention, and are not intended to limit the patent scope of the present invention. Any equivalent structure or equivalent process transformation made using the contents of the present invention specification, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present invention.
Claims
1. Application of hydroquinone derivatives in inhibiting the activity of Klebsiella pneumoniae, wherein the hydroquinone derivatives are:
2. The use of the hydroquinone derivatives according to claim 1 in inhibiting the activity of Klebsiella pneumoniae, characterized in that: The hydroquinone derivatives also include Derivatives of.
3. Application of hydroquinone derivatives in the preparation of anti-Klebsiella pneumoniae drugs, wherein the hydroquinone derivatives are:
4. The use of the hydroquinone derivatives as claimed in claim 3 in the preparation of anti-Klebsiella pneumoniae drugs, wherein the hydroquinone derivatives further include Derivatives of.
Citation Information
Patent Citations
Marine fungus-derived acetophenone compounds and preparation method and application thereof
CN103694209A
Pyrimido-isoquinolin-quinone derivative compounds, and pharmaceutically acceptable salts, isomers and tautomers thereof; pharmaceutical composition; preparation method; and use thereof in the treatment of diseases caused by bacteria and multidrug-resistant bacteria
CN109121411A
Application of paeoniflorin in inhibition of growth of carbapenem-resistant klebsiella pneumoniae
CN110251526A
n-(3-rifamycinyl)carbamates, processes for their preparation and their use in the treatment and prevention of tuberculosis
DE10216719A1
Use of quinones and their derivatives as urease inhibitors, particularly for treating infections with urease-producing bacteria, e.g. Helicobacter pylori
DE10333448A1
